Balado-Simó Pablo, Mansilla-Polo Miguel, Morgado-Carrasco Daniel
Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Dermatol Ther (Heidelb). 2025 Jun;15(6):1283-1306. doi: 10.1007/s13555-025-01410-5. Epub 2025 Apr 20.
Mohs micrographic surgery (MMS) has been shown to achieve very low recurrence rates in skin cancer, and some studies suggest it may improve survival. We conducted a narrative review to assess the impact of MMS on the survival of patients with various skin cancer subtypes. Some retrospective studies suggest that MMS may enhance survival in patients with head and neck melanoma, lentigo maligna, lentigo maligna melanoma, invasive cutaneous squamous cell carcinoma (cSCC) (especially high-risk cSCC), and high-risk dermatofibrosarcoma protuberans, and, possibly, with certain malignant adnexal tumors as well. It is crucial to take these findings into account so as to appropriately prioritize patients and ensure accessibility of MMS. In both Merkel cell carcinoma and leiomyosarcoma, MMS has not consistently demonstrated improved survival compared with wide excision. Evidence regarding improved survival in extramammary Paget's disease remains limited.
莫氏显微外科手术（MMS）已被证明在皮肤癌中能实现非常低的复发率，并且一些研究表明它可能会提高生存率。我们进行了一项叙述性综述，以评估MMS对各种皮肤癌亚型患者生存率的影响。一些回顾性研究表明，MMS可能会提高头颈部黑色素瘤、恶性雀斑样痣、恶性雀斑样痣黑色素瘤、侵袭性皮肤鳞状细胞癌（cSCC）（尤其是高危cSCC）以及高危隆突性皮肤纤维肉瘤患者的生存率，并且可能对某些恶性附属器肿瘤患者也有同样效果。考虑到这些发现对于合理确定患者优先级并确保MMS的可及性至关重要。在默克尔细胞癌和平滑肌肉瘤中，与广泛切除相比，MMS并未始终显示出生存率的提高。关于乳腺外佩吉特病生存率提高的证据仍然有限。
